Drug giant Novartis' Sandoz division plans to launch an EpiPen rival in early 2019. The news, marking an end in sight for the 17-month saga that has stretched since the product, Adamis' Symjepi, was first approved by U.S. regulators.
With a price tag of $250 for a two-pack, Symjepi is priced less than other products in the allergic reaction treatment market.
Symjepi's price is "about 16.5% less" than Mylan's authorized generic EpiPen and a generic EpiPen product put out by Teva, Novartis said in a press release. The product is also set to launch amid an EpiPen shortage.